CoreAge Rx / Time Out
ESTRIOL 0.3%
Every active quantified — estriol 0.3%, vitamin C 5%, hydrolysed hyaluronic acid 0.5% — with the estriol matched exactly to the concentration used in the pivotal topical pilot. A real prescription for a real hormone, which is also why the contraindications below matter more than anything else on this page.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
This is a hormone, not a cosmetic. If you have any history of breast cancer, clotting or unexplained bleeding, read the contraindications section above before you go near the consultation.
The verdict
The prescription here is real and the formula is the best-documented in this company's range. Estriol is an oestrogen: it requires a prescriber, and a prescriber is what the company puts in front of it. This is also the only product of the five to publish a concentration for every active it names — estriol 0.3%, vitamin C 5%, hydrolysed hyaluronic acid 0.5% — which is the standard we have been asking the whole category to meet.
The dose is researched rather than rounded. 0.3% estriol is exactly the strength used in the small clinical pilot that most of the topical-oestrogen skincare literature ultimately traces back to. Somebody read the paper and specified to it, and the supporting choices are sensible: hydrolysed hyaluronic acid at 0.5% is correctly dosed and doing honest vehicle work.
The want it addresses is genuine. Skin carries oestrogen receptors, dermal collagen falls steeply in the years around menopause, and cosmetics serve that badly. What a buyer should understand is what class of product this is: no drug containing estriol has ever been approved by the FDA, the agency's stated position is that the safety and effectiveness of estriol are unknown, and the National Academies have recommended prescribers restrict non-FDA-approved compounded bioidentical hormones to specific medical circumstances. This is a compounded preparation, and it should be used as a supervised treatment with review points rather than a subscription that renews quietly.
One thing on this page needs fixing and it is not pharmacological. A topical oestrogen marketed at mature, thinning, post-menopausal skin should carry its contraindications — breast cancer, clotting history, unexplained bleeding — in plain words, and this page carries none of them. We have printed the list below, and it is the reason this is a conditional recommendation rather than an unqualified one. If you have had breast cancer, this conversation belongs with your oncologist and not with a website.
- The prescription requirement is genuine and correct — estriol is an oestrogen and belongs behind a prescriber.
- Every active carries a published concentration, which no other product in this company's range manages.
- 0.3% estriol matches the concentration used in the pivotal topical pilot study exactly.
- Hydrolysed hyaluronic acid at 0.5% is a sensible, correctly dosed supporting choice.
- The mechanism is real: skin carries oestrogen receptors, and dermal collagen falls steeply in the years around menopause.
- It addresses a genuine want that cosmetics serve badly, with a compounded preparation rather than a marketing claim.
- Directions are sound — thin layer, avoid eyes and broken skin, start slowly, wear sunscreen during the day.
- No contraindications listed at all for a topical hormone — not breast cancer, not clotting, not unexplained bleeding.
- No FDA-approved estriol product exists; the regulator states its safety and effectiveness are unknown.
- The FDA has called safety and efficacy claims for compounded bio-identical hormone preparations false and misleading.
- The pivotal evidence is a very small 1990s pilot whose reported effect sizes are implausibly large.
- Marketed at the demographic with the highest prevalence of prior breast cancer, with no screening mentioned on the page.
- Vitamin C quantified at 5% but with the form unstated, and no pH published.
- No INCI list, no container size, no side effects and no clinical data on the page.
Every active, assessed
- Estriol0.3%
Oestrogen — binds oestrogen receptors in skin, associated with collagen synthesis and dermal thickness
- BENCHMARK
- 0.3% is the concentration used in the pivotal topical pilot; no FDA-approved estriol product exists
- ASSESSMENT
- A real drug at a considered dose, matched to the study that exists rather than to a round number, and the reason the prescription is justified. It is also a hormone with a serious contraindication list that the page does not carry and this review does — read it before the consultation.
- Vitamin C5%
Antioxidant, collagen cofactor, brightening
- BENCHMARK
- 8%–20% for L-ascorbic acid, and only below pH 3.5; derivatives behave differently
- ASSESSMENT
- Quantified, which is more than most, but the form is not stated and the form decides what 5% means. As L-ascorbic acid it is under-dosed and needs a low-pH vehicle; as a derivative it works at neutral pH and sits comfortably here. Ask which.
- Hydrolyzed Hyaluronic Acid0.5%
Humectant, lower molecular weight for better penetration
- BENCHMARK
- 0.1%–2%
- ASSESSMENT
- Fine, correctly dosed, and doing honest vehicle work. Hydrolysed fragments penetrate better than high-molecular-weight HA, which is a sensible choice.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| EstriolOestrogen — binds oestrogen receptors in skin, associated with collagen synthesis and dermal thickness | 0.3% | 0.3% is the concentration used in the pivotal topical pilot; no FDA-approved estriol product exists | A real drug at a considered dose, matched to the study that exists rather than to a round number, and the reason the prescription is justified. It is also a hormone with a serious contraindication list that the page does not carry and this review does — read it before the consultation. |
| Vitamin CAntioxidant, collagen cofactor, brightening | 5% | 8%–20% for L-ascorbic acid, and only below pH 3.5; derivatives behave differently | Quantified, which is more than most, but the form is not stated and the form decides what 5% means. As L-ascorbic acid it is under-dosed and needs a low-pH vehicle; as a derivative it works at neutral pH and sits comfortably here. Ask which. |
| Hydrolyzed Hyaluronic AcidHumectant, lower molecular weight for better penetration | 0.5% | 0.1%–2% | Fine, correctly dosed, and doing honest vehicle work. Hydrolysed fragments penetrate better than high-molecular-weight HA, which is a sensible choice. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%86/100
The mechanism is solid — skin carries oestrogen receptors, dermal collagen falls sharply after menopause, and topical oestrogen raises procollagen and suppresses collagen-degrading enzymes in laboratory work. The dose is matched exactly to the study that exists. What keeps this out of the nineties is the size of that study: a small 1990s pilot reporting effect sizes large enough to invite scepticism, with no modern vehicle-controlled trial to replace it, and no estriol product holding FDA approval.
- FORMULATION INTEGRITYWEIGHT 20%90/100
The estriol concentration matches the studied dose, which is careful work, and the hyaluronic acid is the right molecular weight at the right level. Marked down for vitamin C at 5% with the form unstated — under-dosed if it is L-ascorbic acid, and requiring a low pH that would sit awkwardly in a formula whose pH is not published.
- DISCLOSUREWEIGHT 15%72/100
The best disclosure in the range on the formula itself: every active carries a concentration, which nothing else here manages. It is held well back by what is not on the page — no contraindications for a topical hormone, no side effects, no INCI list, no container size and no clinical data. Publishing the dose of a hormone while omitting who must not use it is the wrong half of the job, and it is the whole reason this criterion is not in the high eighties.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed, and for this product tolerance is not the interesting question. The endpoints that matter for a topical oestrogen are systemic, not cosmetic, and no panel we could run would measure them.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Requires the product in hand over the full trial window.
- COST PER APPLICATIONWEIGHT 10%88/100
$576 a year for a compounded prescription preparation that cannot be bought over the counter at any price, with the consultation, the compounding and delivery included. The premium here has an actual basis, unlike a cosmetic sold behind the same gate. Marked down only because no container size is published, so cost per application still cannot be computed.
What it is
Time Out is a compounded topical sold by CoreAge Rx at $48 a month, marketed for mature skin, loss of firmness, dull tone, fine lines and dehydration. The published formula is estriol 0.3%, vitamin C 5% and hydrolysed hyaluronic acid 0.5%.
Estriol is an oestrogen. That single fact separates this product from everything else we have reviewed from this company and changes what the review has to do.
Here the prescription is doing real work
On this company's cosmetic products we have described the physician review as a dispensing service rather than a regulatory requirement — copper peptide is a cosmetic ingredient, and salicylic acid at monograph strength is a drugstore product. Neither needs a prescriber.
That does not transfer to this product. Estriol is a hormone. It cannot be bought over the counter in the United States at any price, the prescriber is a genuine requirement rather than a service, and this is also the first of the company's skincare products to publish a concentration for every active it names.
0.3% is precisely the estriol concentration used in the small pilot study that most topical-oestrogen skincare ultimately cites. Whoever specified this formula went and read the paper rather than picking a round number. That deserves saying.
What the regulator actually says about estriol
No drug containing estriol has been approved by the FDA, and the agency's stated position is that the safety and effectiveness of estriol are unknown. In the United States it exists only as a compounded preparation.
The FDA has gone further on the category. It has said the claims made about the safety and efficacy of compounded bio-identical hormone preparations are false and misleading and unsupported by medical evidence. The National Academies reviewed the field and recommended that prescribers restrict use of non-FDA-approved compounded bioidentical hormones except in specific medical circumstances, and ACOG has published clinical consensus in the same direction.
None of that means estriol does nothing. It means the evidence required to say what it does, and at what risk, has not been generated — and that a cosmetic indication is a long way from the specific medical circumstances the National Academies had in mind.
The evidence is one small old study
The mechanism is not in doubt. Skin carries oestrogen receptors, dermal collagen falls sharply in the years around menopause, and topical oestrogen is associated with increased procollagen and suppression of collagen-degrading enzymes in laboratory work.
The clinical picture is much thinner. The pivotal reference is a small six-month pilot from the 1990s in pre- and peri-menopausal women, using topical estriol at 0.3%, reporting improvements in elasticity and firmness and reductions in wrinkle depth and pore size.
The reductions in wrinkle depth and pore size reported in that pilot run as high as 61 to 100 percent. Effect sizes of that magnitude in a small, old, uncontrolled-by-modern-standards study are a reason to distrust the measurement, not a reason to buy the product. We are citing the study because it is the basis of the field, not because we find the numbers credible.
A modern, adequately powered, vehicle-controlled trial of topical estriol on facial skin would settle this. As far as we can find, it does not exist.
The contraindications this page should carry
Oestrogen therapy has a contraindication list. It is one of the better-known lists in medicine and it exists because the consequences are serious.
The overlap problem here is the same shape as one we found on a Musely product, and it is just as uncomfortable. This page is marketed at mature skin, thinning skin, post-menopausal skin. That is the population in which prior breast cancer is most prevalent. A meaningful share of the women this copy is written for are survivors, many of them on endocrine therapy specifically designed to suppress oestrogen.
If you have had breast cancer, do not start a topical oestrogen because a website told you it would firm your skin. Systemic oestrogen is generally considered contraindicated after hormone-receptor-positive disease, laboratory work shows estriol produces a robust oestrogenic response in breast cancer cells, and this is a conversation for your oncologist — not for an online intake form and not for us.
We should be even-handed about the magnitude of the risk. Estriol is a weak oestrogen, the applied dose is small, and facial skin is not vaginal mucosa — the route with the most reassuring safety data is not this one, but neither is it the most absorptive. The honest position is that systemic exposure from daily facial application is not well characterised, which is exactly why the contraindications belong on the page rather than being left for a questionnaire nobody can inspect.
The vitamin C is the weak link
Vitamin C at 5%, with the form unstated. If this is L-ascorbic acid it is below the 8 to 20 percent range the evidence uses, and it needs a vehicle below about pH 3.5 to penetrate at all. If it is a derivative — ascorbyl glucoside, sodium ascorbyl phosphate, tetrahexyldecyl ascorbate — the requirements and the evidence are different again, and the label should say which.
There is also a formulation question nobody has answered. A functioning L-ascorbic acid needs a strongly acidic base. That is an awkward environment to share, and no pH is published for this product. Naming the form and the pH would resolve it in one line.
If you are considering it
- Tell the prescriber your full oncological history, including any first-degree relatives, before anything else.
- If you are on tamoxifen or an aromatase inhibitor, do not start this without speaking to the clinician managing that treatment.
- Ask what systemic absorption is expected from daily facial application, and what evidence that answer rests on.
- Ask which form the vitamin C is, and what the pH of the base is.
- Ask the container size so you can work out what a month actually costs.
- Treat it as a supervised treatment with review points, not a subscription that renews quietly.
- Report any unexplained vaginal bleeding, breast changes or leg pain immediately and stop using it.
Where we stand
This is the best-documented product CoreAge Rx sells. The prescription is real, the dose is matched to the study that exists rather than to a round number, every active is quantified, the supporting ingredients are correctly chosen, and it addresses a want — the steep collagen loss that follows menopause — that cosmetics serve badly.
It sits at 85 rather than higher for two reasons, and the second is the important one. The clinical base under topical estriol is one small old study rather than a modern controlled trial, which caps what anybody can promise. And a page selling a topical hormone to post-menopausal women should carry its contraindications in plain words. That is the gap we have filled above, and it is why this is a conditional recommendation: right person, right conversation, right monitoring.
Add the contraindications, name the vitamin C form, publish the pH and the size, and say plainly that this is a non-FDA-approved compounded hormone. That is a paragraph of honest copy, and it would take this to the top of the register.
Who this is for
- A post-menopausal woman with no history of breast, endometrial or ovarian cancer, no clotting history and no unexplained bleeding, who has discussed topical oestrogen explicitly with a clinician who knows her history.
- Someone who understands they are using a compounded, non-FDA-approved hormone preparation and has decided that is acceptable.
- Someone who will treat it as a supervised treatment with review points, not a cosmetic they renew indefinitely.
- You have any history of breast cancer — particularly hormone-receptor-positive disease — or are taking tamoxifen or an aromatase inhibitor. Raise this before anything else.
- You have a history of endometrial or ovarian cancer.
- You have a personal or family history of deep vein thrombosis, pulmonary embolism or stroke, or a known thrombophilia.
- You have unexplained vaginal bleeding that has not been investigated.
- You have active liver disease.
- You are pregnant, could become pregnant, or are breastfeeding.
- You have an intact uterus and are already on systemic oestrogen — cumulative exposure is a conversation for your prescriber, not a website.
This is a hormone, not a cosmetic. If you have any history of breast cancer, clotting or unexplained bleeding, read the contraindications section above before you go near the consultation.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01CoreAge Rx — Time Out product page Price, estriol 0.3%, vitamin C 5%, hydrolysed hyaluronic acid 0.5%, claims and directions, and the absence of contraindications, side effects, INCI, size or clinical data.
- S-02FDA — menopause and hormone therapy consumer information No FDA-approved estriol product; safety and effectiveness of estriol stated as unknown.
- S-03FDA action against compounded hormone therapy claims Regulator's position that safety and efficacy claims for compounded bio-identical hormone preparations are false and misleading.
- S-04National Academies — restrict use of non-FDA-approved compounded bioidentical hormones Recommendation to restrict use except in specific medical circumstances.
- S-05ACOG — compounded bioidentical menopausal hormone therapy clinical consensus Professional body guidance on compounded bioidentical hormone preparations.
- S-06Topical estrogen therapy for aging skin: current evidence and clinical considerations Mechanistic basis and review of the small clinical evidence base for topical oestrogen on skin.
- S-07Effects of estriol on growth and estrogen response element activation in human breast cancer cell lines Estriol produces a robust oestrogenic response in breast cancer cells — the basis for caution in survivors.
- S-08ACOG — treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer Context on oestrogen exposure in breast cancer survivors, and on route-dependent systemic absorption.